Arcoma AB (ARCOMA.ST)
SEK 10.95
(3.3%)
SEK 10.95
(3.3%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 53.25 Million SEK | -92.34% |
| 2022 | 45.98 Million SEK | -6.35% |
| 2021 | 49.09 Million SEK | 17.62% |
| 2020 | 41.74 Million SEK | -2.47% |
| 2019 | 42.79 Million SEK | -9.24% |
| 2018 | 47.15 Million SEK | 0.78% |
| 2017 | 46.79 Million SEK | -16.75% |
| 2016 | 56.2 Million SEK | -0.02% |
| 2015 | 56.22 Million SEK | 2.6% |
| 2014 | 54.79 Million SEK | 4.84% |
| 2013 | 52.26 Million SEK | 1.16% |
| 2012 | 51.66 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 14.05 Million SEK | 6.6% |
| 2024 Q3 | 10.79 Million SEK | -23.25% |
| 2024 Q1 | 13.18 Million SEK | 1381.63% |
| 2023 Q3 | 11.63 Million SEK | -17.07% |
| 2023 Q1 | 14.13 Million SEK | 13.02% |
| 2023 FY | 3.52 Million SEK | -92.34% |
| 2023 Q4 | -1.02 Million SEK | -108.84% |
| 2023 Q2 | 14.03 Million SEK | -0.71% |
| 2022 Q1 | 12.5 Million SEK | -1.83% |
| 2022 FY | 45.98 Million SEK | -6.35% |
| 2022 Q4 | 12.5 Million SEK | 22.75% |
| 2022 Q2 | 11.12 Million SEK | -11.04% |
| 2022 Q3 | 10.18 Million SEK | -8.41% |
| 2021 Q1 | 12.44 Million SEK | -16.1% |
| 2021 Q4 | 12.73 Million SEK | 16.8% |
| 2021 Q2 | 13.02 Million SEK | 4.67% |
| 2021 Q3 | 10.9 Million SEK | -16.3% |
| 2021 FY | 49.09 Million SEK | 17.62% |
| 2020 Q2 | 8.5 Million SEK | -11.42% |
| 2020 Q1 | 9.6 Million SEK | -9.03% |
| 2020 Q3 | 8.79 Million SEK | 3.37% |
| 2020 Q4 | 14.83 Million SEK | 68.69% |
| 2020 FY | 41.74 Million SEK | -2.47% |
| 2019 Q2 | 11.54 Million SEK | 9.99% |
| 2019 Q4 | 10.55 Million SEK | 3.44% |
| 2019 Q3 | 10.2 Million SEK | -11.57% |
| 2019 Q1 | 10.49 Million SEK | -9.05% |
| 2019 FY | 42.79 Million SEK | -9.24% |
| 2018 Q4 | 11.53 Million SEK | 5.29% |
| 2018 FY | 47.15 Million SEK | 0.78% |
| 2018 Q3 | 10.95 Million SEK | -14.47% |
| 2018 Q2 | 12.81 Million SEK | 7.99% |
| 2018 Q1 | 11.86 Million SEK | 2.38% |
| 2017 Q1 | 12.28 Million SEK | -10.03% |
| 2017 FY | 46.79 Million SEK | -16.75% |
| 2017 Q4 | 11.58 Million SEK | 10.35% |
| 2017 Q3 | 10.5 Million SEK | -15.46% |
| 2017 Q2 | 12.42 Million SEK | 1.12% |
| 2016 FY | 56.2 Million SEK | -0.02% |
| 2016 Q4 | 13.65 Million SEK | 11.58% |
| 2016 Q3 | 12.23 Million SEK | -20.63% |
| 2016 Q2 | 15.41 Million SEK | 3.73% |
| 2016 Q1 | 14.86 Million SEK | 5.19% |
| 2015 Q1 | 14.99 Million SEK | 11.93% |
| 2015 Q2 | 15.62 Million SEK | 4.22% |
| 2015 Q3 | 11.47 Million SEK | -26.55% |
| 2015 FY | 56.22 Million SEK | 2.6% |
| 2015 Q4 | 14.12 Million SEK | 23.12% |
| 2014 Q1 | 14.06 Million SEK | 20.26% |
| 2014 Q2 | 15.36 Million SEK | 9.23% |
| 2014 Q3 | 11.64 Million SEK | -24.25% |
| 2014 Q4 | 13.39 Million SEK | 15.05% |
| 2014 FY | 54.79 Million SEK | 4.84% |
| 2013 Q3 | 10.26 Million SEK | 0.0% |
| 2013 FY | 52.26 Million SEK | 1.16% |
| 2013 Q4 | 11.69 Million SEK | 13.99% |
| 2012 FY | 51.66 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 35.725% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 91.296% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 91.296% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -971.684% |
| BICO Group AB (publ) | 2.84 Billion SEK | 98.13% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 74.695% |
| CellaVision AB (publ) | 295.99 Million SEK | 82.009% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | 22.745% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -3967.575% |
| C-Rad AB (publ) | 3.8 Million SEK | -1301.368% |
| Duearity AB (publ) | 21.58 Million SEK | -146.708% |
| Dignitana AB (publ) | 74.73 Million SEK | 28.747% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -1872.296% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.505% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -192.135% |
| Iconovo AB (publ) | 63.35 Million SEK | 15.946% |
| Integrum AB (publ) | 90.57 Million SEK | 41.204% |
| Luxbright AB (publ) | 23.09 Million SEK | -130.623% |
| Mentice AB (publ) | 237.06 Million SEK | 77.536% |
| OssDsign AB (publ) | 175.6 Million SEK | 69.674% |
| Paxman AB (publ) | 133.8 Million SEK | 60.2% |
| Promimic AB (publ) | 48.55 Million SEK | -9.68% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 67.206% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 23.9% |
| ScandiDos AB (publ) | 61.03 Million SEK | 12.756% |
| Sectra AB (publ) | 39.06 Million SEK | -36.323% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 69.488% |
| Senzime AB (publ) | 141.51 Million SEK | 62.371% |
| SpectraCure AB (publ) | 12.12 Million SEK | -339.083% |
| Stille AB | 87.21 Million SEK | 38.944% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 99.043% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 87.923% |